Asia Pacific Antiviral Drugs Market Size & Outlook
Asia Pacific antiviral drugs market, 2018-2030 (US$M)
Related Markets
Asia Pacific antiviral drugs market highlights
- The Asia Pacific antiviral drugs market generated a revenue of USD 9,595.4 million in 2022.
- The market is expected to grow at a CAGR of -1.5% from 2023 to 2030.
- In terms of segment, hiv was the largest revenue generating application in 2022.
- Herpes is the most lucrative application segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2023 to 2030.
Asia Pacific data book summary
| Market revenue in 2022 | USD 9,595.4 million |
| Market revenue in 2030 | USD 8,502.2 million |
| Growth rate | -1.5% (CAGR from 2022 to 2030) |
| Largest segment | Hiv |
| Fastest growing segment | Herpes |
| Historical data covered | 2018 - 2021 |
| Base year for estimation | 2022 |
| Forecast period covered | 2023 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | HIV, Hepatitis, Herpes, Influenza |
| Key market players worldwide | Roche Holding AG, GSK PLC ADR, AbbVie Inc, Merck & Co Inc, Johnson & Johnson, Bristol-Myers Squibb Co, Dr Reddy's Laboratories Ltd ADR, Aurobindo Pharma |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 13.2% of the global antiviral drugs market in 2022.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 8,502.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Antiviral Drugs Market Scope
Antiviral Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific antiviral drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to antiviral drugs market will help companies and investors design strategic landscapes.
Hiv was the largest segment with a revenue share of 34.41% in 2022. Horizon Databook has segmented the Asia Pacific antiviral drugs market based on hiv, hepatitis, herpes, influenza covering the revenue growth of each sub-segment from 2018 to 2030.
The antiviral drugs market in Asia Pacific is expected to decline over the forecast period. However, factors contributing to the market growth are the increasing geriatric population, improving healthcare infrastructure, and entry of new players. Some of the majors operating in Asia Pacific market are GSK plc, AstraZeneca, and Sanofi.
In addition, owing to the region’s large population, the rate of viral infection transmission is also higher. For instance, according to the Singapore Ministry of Health, the country has a higher burden of respiratory infections such as influenza than other diseases. Increasing initiatives for scientific research and positive economic growth coupled with high unmet needs are among the drivers of this market.
Moreover, improving healthcare regulatory scenario in highgrowth countries is expected to attract international players to invest and capitalize on the available opportunities. Positive changes, such as healthcare benefits by the government, increased awareness among the population, and an urge to avail of high-end medical treatment are also expected to drive regional market growth.
Reasons to subscribe to Asia Pacific antiviral drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific antiviral drugs market databook
-
Our clientele includes a mix of antiviral drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific antiviral drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific antiviral drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific antiviral drugs market size, by country, 2018-2030 (US$M)
Asia Pacific Antiviral Drugs Market Outlook Share, 2022 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
